These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31083013)

  • 1. Update on PET imaging biomarkers in the diagnosis of neuropsychiatric disorders.
    Hellwig S; Domschke K
    Curr Opin Neurol; 2019 Aug; 32(4):539-547. PubMed ID: 31083013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets.
    Meyer JH; Cervenka S; Kim MJ; Kreisl WC; Henter ID; Innis RB
    Lancet Psychiatry; 2020 Dec; 7(12):1064-1074. PubMed ID: 33098761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis.
    Hellwig S; Domschke K; Meyer PT
    Curr Opin Neurol; 2019 Aug; 32(4):548-556. PubMed ID: 31107281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Functional imaging in mental disorders].
    Borbély K
    Orv Hetil; 2004 Feb; 145(6):277-89. PubMed ID: 15038321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder.
    Attwells S; Setiawan E; Wilson AA; Rusjan PM; Mizrahi R; Miler L; Xu C; Richter MA; Kahn A; Kish SJ; Houle S; Ravindran L; Meyer JH
    JAMA Psychiatry; 2017 Aug; 74(8):833-840. PubMed ID: 28636705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.
    Dupont AC; Largeau B; Santiago Ribeiro MJ; Guilloteau D; Tronel C; Arlicot N
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28387722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdiagnostic neuroimaging in psychiatry: A review.
    Mitelman SA
    Psychiatry Res; 2019 Jul; 277():23-38. PubMed ID: 30639090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiopharmaceuticals in neurological and psychiatric disorders.
    Valotassiou V; Wozniak G; Sifakis N; Demakopoulos N; Georgoulias P
    Curr Clin Pharmacol; 2008 May; 3(2):99-107. PubMed ID: 18690884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Positron Emission Tomography Neuroimaging.
    Hooker JM; Carson RE
    Annu Rev Biomed Eng; 2019 Jun; 21():551-581. PubMed ID: 31167104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging.
    Downer OM; Marcus REG; Zürcher NR; Hooker JM
    ACS Chem Neurosci; 2020 Aug; 11(15):2192-2200. PubMed ID: 32662626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry.
    Notter T; Coughlin JM; Sawa A; Meyer U
    Mol Psychiatry; 2018 Jan; 23(1):36-47. PubMed ID: 29203847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.
    Nikolaus S; Antke C; Müller HW
    Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography imaging in evaluation of MS pathology in vivo.
    Högel H; Rissanen E; Vuorimaa A; Airas L
    Mult Scler; 2018 Oct; 24(11):1399-1412. PubMed ID: 30091657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.
    Shen LH; Liao MH; Tseng YC
    J Biomed Biotechnol; 2012; 2012():259349. PubMed ID: 22570524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders.
    Newberg A; Alavi A; Reivich M
    Semin Nucl Med; 2002 Jan; 32(1):13-34. PubMed ID: 11839066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.
    Meyer PT; Frings L; Hellwig S
    Curr Opin Neurol; 2014 Aug; 27(4):398-404. PubMed ID: 24978635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of positron emission tomography in psychiatry.
    Parsey RV; Mann JJ
    Semin Nucl Med; 2003 Apr; 33(2):129-35. PubMed ID: 12756645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in psychiatric and neuropsychiatric disorders.
    Dolan RJ; Friston KJ
    Semin Neurol; 1989 Dec; 9(4):330-7. PubMed ID: 2701777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [
    Deussing M; Blume T; Vomacka L; Mahler C; Focke C; Todica A; Unterrainer M; Albert NL; Lindner S; von Ungern-Sternberg B; Baumann K; Zwergal A; Bartenstein P; Herms J; Rominger A; Brendel M
    Neuroimage; 2018 Jan; 165():83-91. PubMed ID: 28988133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.
    Heurling K; Ashton NJ; Leuzy A; Zimmer ER; Blennow K; Zetterberg H; Eriksson J; Lubberink M; Schöll M
    Mol Cell Neurosci; 2019 Jun; 97():34-42. PubMed ID: 30796959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.